AGP Executive Report
Last update: 11 hours agoRegulatory Watch: FDA accepted Teva’s ecopipam NDA for pediatric Tourette syndrome and granted priority review, while also flagging other FDA moves in the Tourette/psychiatry pipeline. Healthcare Workforce: UC physicians in California launched a major attending-doctor unionization push, citing rising labor burden, patient boarding problems, and degraded working conditions. Pharma Safety: A reactor blast at a Telangana pharma unit (Hazelo Lab/Hazelo Pharma) killed two workers and injured nine, with authorities investigating the cause after the fire was contained. Industry & Policy: India’s health minister urged a shift from “Pharmacy of the World” to “Laboratory of the World,” tying AI to drug discovery and safer, privacy-protecting healthcare adoption. Public Health & Prevention: CDC reported nearly 16,000 confirmed cyclosporiasis cases across the U.S., with additional suspected cases under investigation. Mental Health Access: Iceland rolled out a national self-referral digital anxiety service for children aged 5–12, aiming to reduce referral barriers and speed up care. Data & Fraud: Lawmakers renewed focus on healthcare fraud-fighting as costs rise, spotlighting Medicare managed care, prescription drugs, and unnecessary care. Digital Health Oversight: Reports say the FTC is investigating Epic’s data access practices and related employment restrictions, as the EHR company expands AI tools.
Note: AI summary from news headlines; neutral sources weighted more to help reduce bias in the result. Feedback is welcome. Please let us know if you have any comments or suggestions about the AGP Executive Report.
Perspectify News
![<![CDATA[AMO Pharma Aligns With Regulators on Registrational Study for AMO-02 in Myotonic Dystrophy]]>](https://2c717466dc25cd7041c9-8eeda6a8ca964cf210ed223dbc947813.ssl.cf2.rackcdn.com/27759906-936297897-01ea55bd0b69f89fbf84bb40cdd80bd64c2db9f8-1200x628-200x105.png)
